Indeedly, our independent clinical cohort results and TCGA data analysis further corroborated the higher expression levels of NSUN2 and ENO1 in the high‐glucose metabolism group, and the patients with Glycolysis low/NSUN2low/ENO1low signature showed substantial survival benefit compared to that of patients with glycolysis Glycolysishigh/NSUN2high/ENO1high signature in the TCGA‐CRC cohort, respectively. The gene discussed is NSUN2; the disease is colorectal carcinoma.